We are live on ! Find out more

AtriCure

ATRC

Market cap $2.45B

48.17 USD

-0.51

1.05%

At close Updated Aug 26, 4:00 PM EDT

Pre-market

After hours

48.17

0.00

0%

1 day

-1.05%

5 days

1.88%

1 month

28.9%

3 months

67.2%

6 months

52.24%

Year to date

22.66%

1 year

27.2%

5 years

-33.6%

10 years

226.8%

About: AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.

Employees: 1,350

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 25%

Neutral 62.5%

Negative 12.5%

AtriCure to Participate in the 2026 Wells Fargo Health Care Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Wells Fargo Health Care Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, September 8, 2026, at 10:15 a.m. Eastern Standard Time. Interested parties may a.

AtriCure to Participate in the 2026 Wells Fargo Health Care Conference

AtriCure: Promising Cardiovascular Surgical Platform

AtriCure is building a broader surgical platform across appendage management, ablation, and postoperative pain care. They have AtriClip, EnCompass, and cryoSPHERE. These products give them a diversified revenue base. However, we've already seen that catheter-based PFA competition could certainly pressure their growth and margin potential, which is a risk worth considering.

AtriCure: Promising Cardiovascular Surgical Platform

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

AtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials.

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

The Motley Fool

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

This disposition involved 3,500 shares at $38.42 per share, totaling $134,470. The transaction reduced the director's total equity holdings by 20%, based on holdings reported in the Form 4.

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

The Motley Fool

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

Karen Prange disposed of 3,564 shares for a total transaction value of approximately $138,283 on August 5. The sale resulted in a 14% reduction in the director's total direct equity holdings in the company.

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

AtriCure to Participate at Upcoming Investor Conferences

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in two upcoming investor conferences. AtriCure's management is scheduled to participate in meetings at the 11th Annual Needham Virtual MedTech & Diagnostics Conference on Monday, August 10, 2026. AtriCure will also.

AtriCure to Participate at Upcoming Investor Conferences

AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript

AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript

AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript

Zacks Investment Research

AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say

Zacks Investment Research

AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates

AtriCure (ATRC) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.02 per share a year ago.

AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates

AtriCure Q2 Earnings Call Highlights

AtriCure NASDAQ: ATRC reported double-digit revenue growth and a return to GAAP profitability in the second quarter of 2026, with management pointing to strong demand across its pain management, appendage management and open ablation franchises while noting continued pressure in minimally invasive ablation.

AtriCure Q2 Earnings Call Highlights

See News Rankings

Price charts implemented using Lightweight Charts™